1. The Rand Corporation estimates that biosimilar drugs may reduce U.S. health spending by $54 billion over the next decade. The estimate is 20% greater than a similar analysis done by the research organization three years ago. (RAND)

2. GlaxoSmithKline received FDA approval for its shingle vaccine, Shingrix, which could compete with Merck’s Zostavax. (Endpoints News)

3. White House officials have requested that lawmakers create a bipartisan task force on prescription drug pricing. The task force’s mandate would be to develop legislation that could lower prices. (BioCentury)

4. The U.K’s National Institute for Health and Care Excellence recommended GlaxoSmithKline’s “bubble boy” disease treatment Strimvelis. The drug comes with a price tag of $700,000. (Reuters)

5. New data show that Americans’ health is declining and that the retirement age of middle-aged workers is rising. (Bloomberg)